



**41<sup>st</sup> Annual Goldman Sachs Healthcare Conference**  
*Saqib Islam, Chief Executive Officer*

June 9, 2020

NASDAQ: SWTX

# Forward-Looking Statements

This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,” “should” and “could,” and similar expressions or words, identify forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Any forward-looking statements in this presentation are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, risks relating to: (i) the success and timing of our ongoing DeFi and ReNeu clinical trials, (ii) the success and timing of our product development activities and initiating clinical trials, (iii) the success and timing of our collaboration partners’ ongoing and planned clinical trials, (iv) our ability to obtain and maintain regulatory approval of any of our product candidates, (v) our plans to research, discover and develop additional product candidates, (vi) our ability to enter into collaborations for the development of new product candidates, (vii) our ability to establish manufacturing capabilities, and our and our collaboration partners’ abilities to manufacture our product candidates and scale production, (viii) our ability to meet any specific milestones set forth herein, and (ix) uncertainties and assumptions regarding the impact of the COVID-19 pandemic on SpringWorks’ business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.

For further information regarding the risks, uncertainties and other factors that may cause differences between SpringWorks’ expectations and actual results, you should review the “Risk Factors” section(s) of our filings with the Securities and Exchange Commission.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While SpringWorks believes these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

# Pipeline Provides Multiple Opportunities for Value Creation Across Three Distinct Oncology Segments



## ① Late-Stage Rare Oncology

*Two registrational trials ongoing, each supported by strong Phase 2 data and with best-in-class potential*

 **Nirogacestat**  
Desmoid Tumors  
*Phase 3 trial update: 2H20*

 **Mirdametinib**  
NF1-PN  
*Phase 2b trial update: 4Q20-1Q21*

## ② BCMA Combinations in Multiple Myeloma

*Advancing nirogacestat as a cornerstone of BCMA combination therapy across modalities*

 **Nirogacestat + Belamaf**  
BCMA ADC  
*Phase 1b trial initiation: 1Q20*

 **Nirogacestat + ALLO-715**  
BCMA Allogeneic CAR T  
*Phase 1 trial initiation: 2H20*

## ③ Biomarker-Defined Metastatic Solid Tumors

*Precision oncology approach to highly prevalent cancers with near-term clinical POC readouts*

 **Mirdametinib + Lifirafenib**  
RAS/RAF Mutant Solid Tumors  
*Phase 1b trial update: 1H20*

 **BGB-3245**  
RAF Mutant Solid Tumors  
*Initial clinical data: 2021*